In December of 2020, Zenshine pharma  completed A round financing of 100 million RMB. This round of financing will be used to accelerate the clinical research and development of ZX-101A and several existing preclinical projects. Further enrich the R & D pipeline, and create sustainable value in the R&D of small molecules drug for cancer, infectious and inflammatory diseases. Prior to this, Zenshine pharma has received an angel round investment of 32 million RMB, led by Ennovationvc ventures in July 2018.

About Zenshine

Zenshine pharma was founded in 2018, which is a small molecule innovative drug research and development platform in clinical stage. Dr. Yang and Dr. Hao, the founders of the company, has more than 20 years of experience in the R&D of innovative small molecule drugs. The team members also have many years' working experience in the field of biomedicine, with rich experience in drug discovery, biology, clinical research, project management and operation. It is expected that the first product of Zenshine will be sold on the market and enter the industrialization stage by about 2024.